Granisetron vs. Prednisolone Plus Metopimazine for Nausea During Chemotherapy
Author Information
Author(s): Sigsgaard T, Herrstedt J, Andersen L J, Havsteen H, Langer S W, Kjærbøl A-G, Lund H, Kjær M, Dombernowsky P
Primary Institution: Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
Hypothesis
Is granisetron more effective than prednisolone plus metopimazine in preventing nausea during chemotherapy?
Conclusion
Granisetron was more effective than prednisolone plus metopimazine in preventing nausea during the first cycle of chemotherapy, but both treatments showed reduced efficacy over multiple cycles.
Supporting Evidence
- Granisetron was superior to prednisolone plus metopimazine in preventing nausea during the first cycle of chemotherapy.
- Prednisolone plus metopimazine was superior on days 2–5.
- Overall, granisetron was superior on days 1–5.
- The median number of cycles completed with granisetron was five compared to two for prednisolone plus metopimazine.
- Constipation and rash were reported more frequently with granisetron.
- Palpitations were reported more frequently with prednisolone plus metopimazine.
Takeaway
This study looked at two medicines to help stop nausea from chemotherapy. One medicine worked better at first, but both got less effective over time.
Methodology
A randomized, double-blind, double-dummy parallel study comparing granisetron with prednisolone plus metopimazine during nine cycles of chemotherapy.
Limitations
The anti-emetic efficacy of both treatments declined during multiple cycles.
Participant Demographics
Chemotherapy naive women with stage I or II breast cancer.
Statistical Information
P-Value
P < 0.001
Confidence Interval
95% confidence interval 4–6 for granisetron; 95% confidence interval 2–2 for prednisolone plus metopimazine.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website